Proficio Capital Partners LLC Takes Position in Kymera Therapeutics, Inc. $KYMR

Proficio Capital Partners LLC acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, Holdings Channel reports. The firm acquired 11,045 shares of the company’s stock, valued at approximately $1,267,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC increased its position in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the last quarter. Invesco Ltd. raised its stake in Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after purchasing an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Kymera Therapeutics during the second quarter valued at approximately $265,000.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $125.55 on Thursday. The firm has a market cap of $10.44 billion, a price-to-earnings ratio of -38.75 and a beta of 1.95. Kymera Therapeutics, Inc. has a fifty-two week low of $39.84 and a fifty-two week high of $130.05. The firm has a 50 day moving average price of $111.63 and a 200-day moving average price of $93.15.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.95) EPS. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price target on the stock. Mizuho increased their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. B. Riley Financial raised their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.65.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the sale, the director directly owned 461,794 shares in the company, valued at $50,557,207.12. This represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 over the last three months. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.